Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Gwenaël Lorillon"'
Autor:
Céleste Lebbé, Fanélie Jouenne, Maud Salmona, Janine Cherot, Samia Mourah, Aurélie Sadoux, Gwenaël Lorillon, Emmanuelle Bugnet, Jérôme Le Goff, Abdellatif Tazi, Véronique Meignin
Publikováno v:
ERJ Open Research, Vol 6, Iss 2 (2020)
ERJ Open Research
article-version (VoR) Version of Record
ERJ Open Research
article-version (VoR) Version of Record
Langerhans cell histiocytosis (LCH) is currently considered a rare neoplastic disease with an inflammatory component, driven by genomic alterations in the mitogen-activating protein kinase (MAPK) pathway, including BRAFV600E, MAP2K1 mutations and BRA
Autor:
Véronique Meignin, Céleste Lebbé, Gwenaël Lorillon, F. Jouenne, Samia Mourah, C. Reger de Moura, Abdellatif Tazi, Nicolas Dumaz
Publikováno v:
Annals of Oncology. 30:1170-1172
Autor:
Jörg Tost, Gwenaël Lorillon, Céleste Lebbé, Véronique Meignin, Sylvie Chevret, Abdellatif Tazi, Alexandre How-Kit, Florence Mauger, Samia Mourah, Dominique Gossot, Emmanuelle Bugnet
Publikováno v:
European Respiratory Journal. 47:1785-1796
The mitogen-activated protein kinase (MAPK) pathway is constantly activated in Langerhans cell histiocytosis (LCH). Mutations of the downstream kinasesBRAFandMAP2K1mediate this activation in a subset of LCH lesions. In this study, we attempted to ide
Autor:
Abdellatif Tazi, Céleste Lebbé, Laetitia Vercellino, Cécile Pagès, Constance de Margerie-Mellon, Véronique Meignin, Samia Mourah, Alexandre How-Kit, Lauriane Goldwirt, Jörg Tost, Gwenaël Lorillon
Publikováno v:
Blood. 126:2649-2652
To the editor: Langerhans cell sarcoma (LCS) is a rare histiocytic neoplasm with overt malignant cytological features and an aggressive clinical course.[1][1] Disseminated LCS carries a poor prognosis.[1][1] We report a case of a metastatic BRAF V600
Autor:
Cécile Pagès, C. de Margerie-Mellon, Laetitia Vercellino, Abdellatif Tazi, Gwenaël Lorillon, L. Goldwirt, Céleste Lebbé, Samia Mourah, Jörg Tost
Publikováno v:
Annals of Oncology. 27:2305-2307